GlassScriptPhysician profile
Jeffrey S Davidson
NPI 1619920451
$4,092.03
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $568 · 2021: $942 · 2022: $899 · 2023: $1,068 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $521.42 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $428.81 | 2019-2023 | Xarelto |
| Abbvie INC. | $381.40 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $345.08 | 2019-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $293.52 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $288.41 | 2021-2024 | |
| Abbott Laboratories | $278.07 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $276.21 | 2019-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $210.07 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.44 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.19 | 2021-2024 | Jardiance |
| Pfizer INC. | $124.81 | 2019-2021 | |
| Amarin Pharma, INC. | $124.79 | 2019-2021 | |
| Lilly USA, LLC | $102.11 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $45.90 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $41.23 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $40.34 | 2019 | |
| Dexcom, INC. | $30.50 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $30.10 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.95 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.68 | 2022-2023 | Livalo |
| Allergan, INC. | $23.11 | 2019-2020 | |
| Exact Sciences Corporation | $19.43 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $16.52 | 2019 | |
| Astellas Pharma US INC | $16.03 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.39 | 2021 | |
| Hydrofera LLC | $14.95 | 2021 | |
| Merck Sharp & Dohme LLC | $14.55 | 2021 | |
| Boston Scientific Corporation | $12.98 | 2023 | |
| Shire North American Group INC | $12.84 | 2019 | |
| Mylan Specialty L.P. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.